Compare Bristol-Myers Squibb Co (BMY) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs United Airlines Holdings Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while United Airlines Holdings Inc trades at $120.65 (market cap $39.06B). The key difference: Bristol-Myers Squibb Co is far larger — about 3× United Airlines Holdings Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| BMY | UAL | |
|---|---|---|
Market Cap | $116.30B | $39.06B |
Sector | Health | Industrials |
52-Week High | $62.37 | $136.11 |
52-Week Low | $42.60 | $84.57 |
Enterprise Value | $152.24B | $55.87B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
United Airlines (UAL) trades at $121.16, down 3.84% amid sector volatility, with strong fundamentals including a P/E of 10.84 and net income margin of 6.06%. Recent earnings beats and a bullish analyst consensus (66% buy ratings) support a $160.88 price target. Cash flow trends show operational strength despite net outflows, while technical indicators signal near-term support at $120.
Outlook remains positive with projected revenue growth to $60.5B in 2026, though risks include fuel cost spikes and competitive pressures. The stock offers value with low valuation multiples and consistent earnings outperformance, positioning it for recovery if macroeconomic headwinds ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
